文献速递泌尿男性生殖肿瘤

ODX治疗去势抵抗性前列腺癌骨转移患者的随机双盲剂量探索II期多中心研究

A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with castration-resistant prostate cancer and skeletal metastases.
PubMed 文献 · Eur J Cancer · 2022-12-20

本研究评估新型骨靶向细胞毒药物ODX在去势抵抗性前列腺癌骨转移中的疗效与安全性。55例进展期患者随机接受3、6、9 mg/kg ODX静脉输注每2周一次共10周期。主要终点为12周时骨碱性磷酸酶(B-ALP)和I型前胶原氨基端前肽(S-P1NP)相对基线的变化。ODX耐受良好,无药物相关严重不良事件,各剂量组疗效与安全性无显著差异。

要点

  • 12周时B-ALP下降在3、6、9 mg/kg组分别为6/15(40%)、8/12(67%)、5/12(42%)。
  • 12周时P1NP下降在3、6、9 mg/kg组分别为8/15(53%)、8/12(67%)、4/12(33%)。
  • ODX耐受良好,无药物相关严重不良事件,各剂量组疗效与安全性无显著差异。

核心结论

  • ODX在所有三个剂量下耐受良好,并对骨恶性循环相关标志物显示出抑制作用。
  • 以骨扫描指数评估的转移负荷减少支持上述发现。
  • 正在计划持续ODX治疗至疾病进展的研究(ClinicalTrials.gov标识符:NCT02825628)。

研究设计与样本

  • 随机、双盲、剂量探索、II期多中心研究。
  • 入组进展期去势抵抗性前列腺癌骨转移患者,随机接受10周期ODX静脉输注每2周一次,剂量分别为3、6、9 mg/kg。
  • 主要目标为评估12周时B-ALP和S-P1NP相对基线的变化。
  • 采用宽泛入选标准及双盲设计以确保客观招募患者进行疗效评估。
  • ODX治疗期间无患者接受骨保护剂。

主要发现

  • 55例患者随机分配至ODX 3、6、9 mg/kg组,分别为21、20、14例;第3组患者数较少是由于研究末期招募率过低。
  • 中位治疗时间在3、6、9 mg/kg组分别为14、13、14周。
  • 12周时B-ALP下降在3、6、9 mg/kg组分别见于6/15(40%)、8/12(67%)、5/12(42%)患者。
  • 12周时P1NP下降在3、6、9 mg/kg组分别见于8/15(53%)、8/12(67%)、4/12(33%)患者。
  • 12周时B-ALP和P1NP中位下降幅度在3、6、9 mg/kg组分别为37%、14%、43%和51%、40%、64%。

关键数值与推荐

  • 12周时血清C末端肽下降见于绝大多数患者,骨扫描指数下降见于约三分之一患者。
  • ODX耐受良好,无药物相关严重不良事件。
  • 各研究组间疗效与安全性无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 第3组患者数较少是由于研究末期招募率过低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: This study aimed to assess the efficacy and safety of ODX, a novel, cytotoxic, bone-targeting drug candidate, in castration-resistant prostate cancer bone metastatic disease. METHODS: Patients with progressive disease were randomised to ten cycles of ODX, intravenous infusion Q2W (3, 6, and 9 mg/kg, respectively). The primary objective was to assess the relative change from baseline in bone alkaline phosphatase (B-ALP) and serum-aminoterminal-propeptide of Type I procollagen (S-P1NP) at 12 weeks. The inclusion criteria selected were broad, and a double-blind design was used to ensure objective recruitment of patients for the assessment of efficacy. None of the patients received bone-protecting agents during the ODX treatment period. RESULTS: Fifty-five 21,20 and 14) patients were randomised to ODX (3, 6 and 9 mg/kg), respectively. The lower number of patients in arm 3 was due to too low a recruitment rate towards the end of the study. The median treatment time were 14, 13 and 14 weeks, respectively. The decrease in B-ALP at 12 weeks in study arms 3, 6 and 9 mg/kg was seen in 6/15 (40%), 8/12 (67%) and 5/12 (42%) patients, respectively, whereas the corresponding numbers for P1NP were 8/15 (53%), 8/12 (67%), and 4/12 (33%), respectively. The median decrease in B-ALP and P1NP at 12 weeks for study arms 3, 6 and 9 mg/kg were 37%, 14% and 43%, respectively, and 51%, 40% and 64%, respectively. The decrease in serum C-terminal telopeptide at 12 weeks was seen in the vast majority of patients and in about one-third of patients in bone scan index. ODX was well tolerated, and no drug-related serious adverse events occurred. There were no significant differences between study arms regarding efficacy and safety. CONCLUSIONS: ODX was well tolerated and demonstrated inhibitory effects on markers related to the vicious cycle in bone at all three doses. The reduction in metastatic burden, assessed with bone scan index, supports this finding. Studies with continued ODX treatment until disease progression are being planned (ClinicalTrials.gov Identifier: NCT02825628).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Thellenberg-Karlsson C, Vjaters E, Kase M, et al. A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with castration-resistant prostate cancer and skeletal metastases. Eur J Cancer. 2022. PMID: 36682096. doi:10.1016/j.ejca.2022.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。